



May 10, 2024

BSE Limited

Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001

National Stock Exchange of India Ltd.,

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051

Dear Sir/Madam,

Re: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Subject: Re-launch of Mirabegron Extended-Release (ER) Tablets 25 mg in the United States.

We would like to notify you that the US Court has lifted the Temporary Restraining Order and denied Astellas' request for a preliminary injunction on Mirabegron ER Tablets. Thereafter, shipment of the product has now resumed.

Mirabegron ER Tablets, 25 mg are a generic equivalent of Myrbetriq® Extended-Release Tablets, 25 mg of Astellas Pharma Global Development, Inc., and were launched by Lupin in April 2024.

This may kindly be considered as a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

For LUPIN LIMITED

R. V. SATAM

**COMPANY SECRETARY
(ACS - 11973)**